BRPI0822033A2 - Composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, kit - Google Patents
Composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, kitInfo
- Publication number
- BRPI0822033A2 BRPI0822033A2 BRPI0822033-6A BRPI0822033A BRPI0822033A2 BR PI0822033 A2 BRPI0822033 A2 BR PI0822033A2 BR PI0822033 A BRPI0822033 A BR PI0822033A BR PI0822033 A2 BRPI0822033 A2 BR PI0822033A2
- Authority
- BR
- Brazil
- Prior art keywords
- salt
- compound
- kit
- pharmaceutical composition
- pharmaceutical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 150000003839 salts Chemical class 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1424207P | 2007-12-17 | 2007-12-17 | |
| EP08101961 | 2008-02-25 | ||
| PCT/EP2008/067621 WO2009077527A1 (en) | 2007-12-17 | 2008-12-16 | Anthelmintic agents and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0822033A2 true BRPI0822033A2 (pt) | 2015-07-21 |
| BRPI0822033B1 BRPI0822033B1 (pt) | 2018-12-11 |
Family
ID=39563449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0822033A BRPI0822033B1 (pt) | 2007-12-17 | 2008-12-16 | composto ou sal do mesmo, composição farmacêutica, e, uso de um composto ou sal |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8569495B2 (pt) |
| EP (1) | EP2234973B1 (pt) |
| CN (1) | CN101896459B (pt) |
| AR (1) | AR069772A1 (pt) |
| AU (1) | AU2008337482B2 (pt) |
| BR (1) | BRPI0822033B1 (pt) |
| CA (1) | CA2709407A1 (pt) |
| ES (1) | ES2501544T3 (pt) |
| NZ (1) | NZ586087A (pt) |
| PE (1) | PE20091453A1 (pt) |
| TW (1) | TW200938203A (pt) |
| UY (1) | UY31539A1 (pt) |
| WO (1) | WO2009077527A1 (pt) |
| ZA (1) | ZA201004261B (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2413701A4 (en) | 2009-03-31 | 2012-10-03 | Univ Vanderbilt | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGUES AS GLYT1 INHIBITORS, METHODS OF MAKING THEM AND USE THEREOF IN THE TREATMENT OF PSYCHIATRIC DISORDERS |
| ES2556460T3 (es) * | 2010-09-29 | 2016-01-18 | Sk Biopharmaceuticals Co., Ltd. | Derivados novedosos de metilciclohexano y usos de los mismos |
| EP2468096A1 (en) | 2010-12-21 | 2012-06-27 | Intervet International BV | Anthelmintic combinations |
| NZ716598A (en) * | 2012-11-20 | 2017-02-24 | Merial Inc | Anthelmintic compounds and compositions and method of using thereof |
| FR3000065A1 (fr) * | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
| NZ726874A (en) | 2014-05-19 | 2018-03-23 | Merial Inc | Anthelmintic compounds |
| JP2017519801A (ja) * | 2014-07-11 | 2017-07-20 | インターベット インターナショナル ベー． フェー． | 犬糸状虫に対する駆虫薬の使用 |
| WO2016005576A1 (en) * | 2014-07-11 | 2016-01-14 | Intervet International B.V. | Use of anthelmintic agents against dirofilaria immitis |
| ES2907461T3 (es) | 2015-01-20 | 2022-04-25 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos |
| RU2018145734A (ru) | 2016-06-08 | 2020-07-14 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Химические соединения в качестве ингибиторов atf4 пути |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| EP4092013A1 (en) | 2017-06-20 | 2022-11-23 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| CN107987012A (zh) * | 2018-01-29 | 2018-05-04 | 田元强 | 一种4-苄基哌啶类酰胺化合物及其在防治植物线虫病害中的应用 |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| US12318382B2 (en) | 2018-10-17 | 2025-06-03 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| EP3976101A4 (en) | 2019-05-31 | 2023-06-21 | Imbria Pharmaceuticals, Inc. | FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
| CN117586207A (zh) * | 2023-11-27 | 2024-02-23 | 浙江东亚药业股份有限公司 | 一种酮康唑侧链的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB819681A (en) * | 1957-01-24 | 1959-09-09 | Wellcome Found | Improvements in and relating to quaternary ammonium compounds and the preparation thereof |
| GB1032251A (en) * | 1961-06-22 | 1966-06-08 | Wellcome Found | Piperazine compounds and their preparation |
| CH542828A (de) * | 1970-09-02 | 1973-10-15 | Agripat Sa | Verfahren zur Herstellung neuer Thioharnstoffe |
| US4247710A (en) * | 1978-02-08 | 1981-01-27 | Hoffmann-La Roche Inc. | Intermediate in the production of adrenergic blocking agents |
| DE19529604A1 (de) * | 1995-08-11 | 1997-02-13 | Bayer Ag | Endoparasitizide Mittel auf Basis von Didepsipeptiden, neue Didepsipeptide und ein Verfahren zu ihrer Herstellung |
| FR2740134B1 (fr) * | 1995-10-18 | 1998-01-09 | Pf Medicament | Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant |
| US6331545B1 (en) * | 1998-12-18 | 2001-12-18 | Soo S. Ko | Heterocycyclic piperidines as modulators of chemokine receptor activity |
-
2008
- 2008-12-10 TW TW097148018A patent/TW200938203A/zh unknown
- 2008-12-16 CA CA2709407A patent/CA2709407A1/en not_active Abandoned
- 2008-12-16 US US12/808,897 patent/US8569495B2/en not_active Expired - Fee Related
- 2008-12-16 WO PCT/EP2008/067621 patent/WO2009077527A1/en not_active Ceased
- 2008-12-16 EP EP08863299.7A patent/EP2234973B1/en active Active
- 2008-12-16 NZ NZ586087A patent/NZ586087A/en not_active IP Right Cessation
- 2008-12-16 PE PE2008002081A patent/PE20091453A1/es not_active Application Discontinuation
- 2008-12-16 AU AU2008337482A patent/AU2008337482B2/en not_active Ceased
- 2008-12-16 BR BRPI0822033A patent/BRPI0822033B1/pt not_active IP Right Cessation
- 2008-12-16 ES ES08863299.7T patent/ES2501544T3/es active Active
- 2008-12-16 CN CN2008801201693A patent/CN101896459B/zh not_active Expired - Fee Related
- 2008-12-17 UY UY31539A patent/UY31539A1/es unknown
- 2008-12-17 AR ARP080105480A patent/AR069772A1/es not_active Application Discontinuation
-
2010
- 2010-06-15 ZA ZA2010/04261A patent/ZA201004261B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101896459A (zh) | 2010-11-24 |
| PE20091453A1 (es) | 2009-10-03 |
| TW200938203A (en) | 2009-09-16 |
| UY31539A1 (es) | 2009-08-03 |
| AR069772A1 (es) | 2010-02-17 |
| ZA201004261B (en) | 2011-02-23 |
| EP2234973B1 (en) | 2014-07-02 |
| NZ586087A (en) | 2011-08-26 |
| WO2009077527A1 (en) | 2009-06-25 |
| AU2008337482B2 (en) | 2013-09-12 |
| AU2008337482A1 (en) | 2009-06-25 |
| US20110021506A1 (en) | 2011-01-27 |
| BRPI0822033B1 (pt) | 2018-12-11 |
| EP2234973A1 (en) | 2010-10-06 |
| CA2709407A1 (en) | 2009-06-25 |
| US8569495B2 (en) | 2013-10-29 |
| CN101896459B (zh) | 2013-07-24 |
| ES2501544T3 (es) | 2014-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0810696A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0818193A2 (pt) | composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto | |
| BRPI0810161A2 (pt) | Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto | |
| BRPI0607545A2 (pt) | composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
| BRPI0815709A2 (pt) | composro, composição farmacêutica, e, uso de um composto. | |
| BRPI0609802A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BRPI0716171A2 (pt) | composto, composiÇço farmacÊutica e uso de um composto. | |
| BRPI0917540A2 (pt) | composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável | |
| BRPI0919942A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0907562A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0921375A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0917001A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica | |
| BRPI0716698A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
| BRPI0917579A2 (pt) | composto, composição farmacêutica, métodos, e, uso de um composto | |
| BRPI0812942A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
| BRPI0821115A2 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| BRPI0809977A2 (pt) | Uso de um composto, compostos e composição farmacêutica que o contém | |
| BRPI0614205A2 (pt) | composto, composição farmacêutica, e, uso de composto | |
| BRPI0618904A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| BRPI0810019A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0921879A2 (pt) | composto, composição farmacêutica , e, uso de um composto | |
| BRPI1013988A2 (pt) | composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo | |
| BRPI0819696A2 (pt) | Compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto | |
| BRPI0819299A2 (pt) | Uso de composição, e, composição contendo proteína | |
| BRPI0716327A2 (pt) | Composto de fenilpropionamida e uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2008, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2649 DE 13-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |